
Paul Bolno, Wave Life Sciences CEO
An early-stage fail highlights ongoing ALS drug development challenges, despite recent Biogen OK
A Takeda partner reported an early-stage ALS trial failure Tuesday morning and opted to discontinue the program entirely, serving as a reminder that despite two recent FDA approvals, challenges remain in tackling the universally fatal disease.
Wave Life Sciences said its program, dubbed WVE-004, did not show any clinical benefit when compared to placebo in a subset of ALS patients with specific genetic mutations. The compound additionally failed to show a benefit for patients with frontotemporal dementia in a separate benefit analysis.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters